Trial intelligence / Profile preview

Incidence of skin sensitization with rivastigmine transdermal patch in dementia

TCTR20200911003Phase 4Recruiting

Sponsor
Berlin Pharmaceutical
Start
Sep 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, single-arm trial of rivastigmine in Dementia, sponsored by Berlin Pharmaceutical. Primary endpoint: Incidence of skin sensitization. Started Sep 2020; status: recruiting.

02

Drugs

rivastigmine
03

Conditions

Dementia

Beyond the preview

Go deeper on TCTR20200911003.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on TCTR20200911003.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call